Glycated haemoglobin testing, also known as HbA1c testing or A1c testing, is commonly performed to diagnose prediabetes and diabetes and monitor effectiveness of treatment. It provides clinicians with an indication of a patient’s average blood sugar level over the past 2-3 months. The standard A1c test measures what percentage of a person’s hemoglobin — the oxygen-carrying protein inside red blood cells — is coated with sugar.
The Glycated Haemoglobin Testing Market is estimated to be valued at USD 239 Mn in 2024 and is expected to reach USD 426 Mn by 2031, growing at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031.
Key Takeaways
Key players operating in the Glycated Haemoglobin Testing market are Abbott Laboratories,Roche Diagnostics,Siemens Healthineers,Tosoh Corporation,Bio-Rad Laboratories.
The increasing prevalence of diabetes across the world coupled with favourable government initiatives to spread awareness about diabetes and its management are some of the major factors driving market growth. Point of care testing devices are also gaining popularity due to advantages such as real time results and portability.
Technological advancements include the development of A1c point-of-care testing devices, microfluidics-based testing, and wearable and non-invasive A1c monitoring devices which provide faster and more convenient testing options for patients.
Market Drivers
The increasing geriatric population globally that is more susceptible to developing diabetes is a major factor fueling the growth of this market. As per WHO, the number of people aged 60 years and older is expected to reach 2 billion by 2050 from 900 million in 2015. Growing awareness initiatives by governments and healthcare organizations also encourage regular screening and monitoring of blood sugar levels.
Challenges in the Glycated Haemoglobin Testing Market
The glycated haemoglobin testing market faces a few challenges. Access and affordability are crucial issues, as the tests can be quite expensive, putting them out of reach for many patients, especially in developing regions. Limited awareness is also a challenge, as many patients and healthcare practitioners remain unaware of the importance of HbA1c tests for managing diabetes. Complications arising from inaccurate or flawed testing methods pose another challenge. There is scope for standardizing quality control and testing protocols to minimize errors.
SWOT Analysis
Strength: The non-fasting nature and long-term glucose monitoring ability of HbA1c tests make them very convenient for patients and clinicians.
Weakness: Cost remains a significant barrier, limiting adoption. Sample storage and transportation requirements can pose issues for remote areas.
Opportunity: Rising diabetes prevalence is boosting demand for reliable and affordable monitoring solutions. Growing awareness offers an opportunity to further popularize HbA1c testing.
Threats: Alternative emerging techniques may challenge the dominance of HbA1c testing if found more cost-effective or convenient. Regulations need to keep up with latest industry advancements.
Geographically, North America currently holds the major share of the glycated haemoglobin testing market, owing to high diabetes prevalence, advanced healthcare infrastructure and widespread medical insurance. Asia Pacific is poised to experience the fastest growth during the forecast period, driven by improving accessibility to diagnostic services, rising disposable incomes and growing health consciousness in developing countries like India and China.
The United States represents the most significant market for glycated haemoglobin testing in terms of value. This is attributed to the large diabetic patient pool, widespread health insurance coverage and clinical guidelines recommending regular HbA1c monitoring. However, other developed regions like Western Europe and Japan also account for major shares and are expected to remain lucrative markets going forward.
What Are The Key Data Covered In This Glycated Haemoglobin Testing Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Glycated Haemoglobin Testing growth between 2024 and 2031.
:- Accurate calculation of the size of the Glycated Haemoglobin Testing and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Glycated Haemoglobin Testing Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Glycated Haemoglobin Testing vendors
FAQ’s
Q.1 What are the main factors influencing the Glycated Haemoglobin Testing ?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Glycated Haemoglobin Testing companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Glycated Haemoglobin Testing distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.